Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570373 · ClinicalTrials.gov registry record · Phase 1
A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02570373: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT02570373 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570373, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
Primary Outcome
The composition of the glycoforms will be quantified and evaluated over time.
Interventions
- DRUG Guselkumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-09-25 |
| Est. Completion | 2016-01-12 |
| Phase | Phase 1 |
What the finished NCT02570373 record still lists
NCT02570373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Guselkumab is the first listed.
NCT02570373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02570373 about?
NCT02570373 is a clinical study titled "A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants". The purpose of this study is to characterize the elimination of guselkumab glycoform variants following a single intravenous (IV) administration of guselkumab at a 10 milligram per kilogram (mg/kg) dose in healthy participants.
What is the current status of trial NCT02570373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-09-25. Estimated completion is 2016-01-12.
What interventions are being tested in trial NCT02570373?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT02570373?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02570373's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI